Patents.us
Patents/US12168005

US12168005No. 12,168,005utilityGranted 12/17/2024

Claims (13)

Claim 1 (Independent)

1. A method of treating cancer in a mammalian subject in need thereof, said cancer contains cancer cells characterized by presence of wild type isocitrate dehydrogenase 1 (IDH1) enzyme and absence of mutant IDH1 enzyme, the method comprising administering to said subject a pharmaceutical composition comprising compound AG-120 having the formula

Claim 2 (Independent)

2. A method of treating cancer in a mammalian subject in need thereof, said cancer contains cancer cells characterized by presence of wild type isocitrate dehydrogenase 1 (IDH1) enzyme and absence of mutant IDH1 enzyme, the method comprising administering to said subject a pharmaceutical composition comprising compound AG-120 having the formula

Claim 13 (Independent)

13. A method of treating cancer in a mammalian subject in need thereof, said cancer contains cancer cells characterized by presence of wild type isocitrate dehydrogenase 1 (IDH1) enzyme and absence of mutant IDH1 enzyme, the method consisting of administering to said subject compound AG-120 having the formula

Show 10 dependent claims
Claim 3 (depends on 1)

3. The method of claim 1 , wherein said cancer cells further have a lower Magnesium 2+ (Mg 2+ ) concentration compared to Mg 2+ concentration in serum.

Claim 4 (depends on 1)

4. The method of claim 1 , said cancer comprises one or more of pancreatic cancer, colon cancer, lung cancer and ovarian cancer.

Claim 5 (depends on 1)

5. The method of claim 1 , said wild type IDH1 enzyme is overexpressed in said cancer cells compared to non-cancerous cells, wherein said cancer cells and said non-cancerous cells are of the same cell type.

Claim 6 (depends on 1)

6. The method of claim 1 , said cancer cells further lack mutant IDH1 gene.

Claim 7 (depends on 1)

7. The method of claim 1 , said method further comprising administering to the subject an anti-cancer compound that reduces cancer.

Claim 8 (depends on 2)

8. The method of claim 2 , wherein said cancer cells further have a lower Magnesium 2+ (Mg 2+ ) concentration compared to Mg 2+ concentration in serum.

Claim 9 (depends on 2)

9. The method of claim 2 , said cancer comprises one or more of pancreatic cancer, colon cancer, lung cancer and ovarian cancer.

Claim 10 (depends on 2)

10. The method of claim 2 , said wild type IDH1 enzyme is overexpressed in said cancer cells compared to non-cancerous cells, wherein said cancer cells and said non-cancerous cells are of the same cell type.

Claim 11 (depends on 2)

11. The method of claim 2 , said cancer cells further lack mutant IDH1 gene.

Claim 12 (depends on 2)

12. The method of claim 2 , said method further comprising administering to the subject an anti-cancer compound that reduces cancer.

Full Description

No description text available for this patent.

Citations

This patent cites (18)

  • US5851789
  • US6238878
  • US6632979
  • US6905839
  • US9662327
  • US9850277
  • US9968595
  • US2013/0190249
  • US2016/0137585
  • US2017/0014396
  • US2018/0071302
  • US2018/0296583
  • US2018/0353514
  • US2019/0046512
  • US2019/0076425
  • US2019/0133980
  • US2022/0280538
  • USWO2019012328